New Delhi | November 26, 2025 | SKY LINK TIMES
Pharma Innovation Revolution:
India is rapidly transitioning from its status as the “Pharmacy of the World” to becoming an innovation-driven pharmaceutical powerhouse, according to Dr. R Chandrashekar, Joint Drugs Controller at the Central Drugs Standard Control Organization (CDSCO). Speaking on November 26 at the 18th CPHI & PMEC India event in Greater Noida, he highlighted that the next five years are crucial in shaping India’s leadership in global healthcare innovation.
Table of Contents
Government Reforms Powering Pharma Innovation
Dr. Chandrashekar emphasized that a series of regulatory reforms and government initiatives have strengthened India’s R&D ecosystem. These include:
Streamlined approval systems
Reduced regulatory layers
Decriminalisation of non-serious regulatory offences
Recommendation of R&D projects worth ₹5,000 crore
A new ₹1,00,000 crore hospital finance scheme to support research infrastructure
He said these policy measures reflect a strong national push toward advancing drug development and accelerating innovation-based growth.
“India’s pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem, with growing emphasis on biosimilars, peptides, complex generics and next-generation biologics,” he stated
Industry Leaders Call for Innovation Beyond Generics
Namit Joshi, Chairman of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), noted that India must evolve beyond traditional generics manufacturing. He urged companies to embrace cross-domain insights and advanced technologies to shape the future of global healthcare.
Joshi highlighted that high-value therapy segments present substantial opportunities for Indian manufacturers, especially as major patents expire.
“The future lies in value-driven innovation, advancing capabilities in peptides, complex generics, biosimilars, biologics, targeted drug delivery systems, and cell and gene therapies,” he said.
He also pointed to the competitive potential of upcoming drug categories such as GLP-1 inhibitors, which are transforming global health outcomes, particularly in diabetes and obesity treatment.
Also Read:https://skylinktimes.in/india-invests-rs-720-crore-in-quantum-leap/
Stronger IP Protection to Boost India’s Global Position
According to Anil Matai, Director General of the Organization of Pharmaceutical Producers of India (OPPI), enhanced intellectual property systems and reduced patent infringements are helping India move closer to becoming a global pharma innovation hub.
“The shift toward a research-oriented future is already visible,” he said, emphasizing the government’s goal to ‘discover in India, innovate in India, and innovate for the world.”
Outlook
With its strong manufacturing base, improving regulatory structure, and rising R&D focus, experts say India could soon compete with global biotech leaders and significantly impact worldwide healthcare innovation.
For More Info Stay Tuned: https://skylinktimes.in
